December 8, 2025Blood

Low dose tocilizumab for mitigation of cytokine release syndrome with bispecific antibodies in relapsed/refractory multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

ADAndriy DerkachMemorial Sloan Kettering Cancer Center ALAlexander M. LesokhinMemorial Sloan Kettering Cancer Center SMSham MailankodyMemorial Sloan Kettering Cancer Center

Discussion

Member takes

Implication

Observational analysis shows lower cytokine release syndrome rates in patients with myeloma receiving tocilizumab prophylaxis, indicating effective mitigation during treatment.

Key Points

Cytokine release syndrome rates significantly decreased to 21% with low-dose tocilizumab during treatment.
Prophylactic use of tocilizumab reduced the incidence of CRS with an odds ratio of 0.2 in patients receiving bispecific antibodies.
Analysis involved 64 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies and tocilizumab.
Results support the recommendation of tocilizumab in current guidelines to prevent serious CRS effects.

Cite This Study

Derkach et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7d8 https://doi.org/10.1182/blood-2025-2210

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis shows lower cytokine release syndrome rates in patients with myeloma receiving tocilizumab prophylaxis, indicating effective mitigation during treatment.

Low dose tocilizumab for mitigation of cytokine release syndrome with bispecific antibodies in relapsed/refractory multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Low dose tocilizumab for mitigation of cytokine release syndrome with bispecific antibodies in relapsed/refractory multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider